CCN2 (CTGF) Gene Polymorphism Is a Novel Prognostic Risk Factor for Cardiovascular Outcomes in Hemodialysis Patients | Zendy

Mario Cozzolino | Zendy; Maria Luisa Biondi | Zendy; Elena Banfi | Zendy; Bruce L. Riser | Zendy; Florjan Mehmeti | Zendy; Daniele Cusi | Zendy; Maurizio Gallieni | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

CCN2 (CTGF) Gene Polymorphism Is a Novel Prognostic Risk Factor for Cardiovascular Outcomes in Hemodialysis Patients

Author(s) -

Mario Cozzolino,

Maria Luisa Biondi,

Elena Banfi,

Bruce L. Riser,

Florjan Mehmeti,

Daniele Cusi,

Maurizio Gallieni

Publication year - 2010

Publication title -

blood purification

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.686

H-Index - 57

eISSN - 1421-9735

pISSN - 0253-5068

DOI - 10.1159/000320706

Subject(s) - ctgf , medicine , dyslipidemia , gastroenterology , genotype , gene polymorphism , risk factor , connective tissue , hemodialysis , growth factor , pathology , biology , gene , disease , genetics , receptor

The very high cardiovascular (CV) mortality and morbidity rates in hemodialysis (HD) patients are greatly related to atherosclerosis. CCN2 (connective tissue growth factor/CTGF) is a profibrotic factor that is secreted by endothelial cells, involved in atherogenesis, promoting fibroblast proliferation and matrix production. CCN2 protein is significantly increased in complicated fibrous plaques and enhances monocyte migration into atherosclerotic lesions. The aim of this study was to investigate a possible association between CCN2 gene polymorphism and CV morbidity and mortality in HD patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research